Hoth Therapeutics(HOTH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

HOTH Hoth Therapeutics

交易中 06-01 09:47:11 EDT

1.36

+0.00

0.00%

最高1.36	最低1.36	成交量0.00
今开1.36	昨收1.36	日振幅0.00%
总市值2,601万	流通市值2,526万	总股本1,913万
成交额0.00	换手率0.00%	流通股本1,857万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"HOTH","market":"US","secType":"STK","nameCN":"Hoth Therapeutics","latestPrice":1.36,"timestamp":1780321631837,"preClose":1.36,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":18574000,"shares":19127643,"eps":-0.804114,"marketStatus":"交易中","change":0,"latestTime":"06-01 09:47:11 EDT","open":1.36,"high":1.36,"low":1.36,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.804114,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1780344000000},"marketStatusCode":2,"symbolChange":{"newSymbol":"RKTO","executeDate":"2026-05-28"},"adr":0,"adrRate":0,"listingDate":1550206800000,"exchange":"NASDAQ","adjPreClose":1.36,"volumeRatio":0},"requestUrl":"/m/hq/s/HOTH","defaultTab":"news","newsList":[{"id":"1124077339","title":"火箭一号股票更名首日盘前飙涨50%至2.04美元，从Hoth Therapeutics蜕变启航","url":"https://stock-news.laohu8.com/highlight/detail?id=1124077339","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124077339?lang=zh_cn&edition=full","pubTime":"2026-05-28 17:57","pubTimestamp":1779962236,"startTime":"0","endTime":"0","summary":"火箭一号的股价在盘前交易中强势跃升50%，触及每股2.04美元。这一显著涨幅正值该股票以全新名称启动交易，正式告别其旧称Hoth Therapeutics。更名标志着公司发展进入新阶段，市场对此反应积极，投资者热情高涨，推动股价在开盘前即大幅上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100827537","title":"Hoth Therapeutics 计划持续推进生物技术项目，或考虑将资产注入独立子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1100827537","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100827537?lang=zh_cn&edition=full","pubTime":"2026-05-19 20:22","pubTimestamp":1779193338,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics 宣布，公司将继续推进其生物技术项目。同时，公司正考虑将部分资产置于一个独立的子公司中。这一举措旨在优化资产结构，可能为特定项目或技术平台的未来发展提供更清晰的战略聚焦和运营灵活性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HOTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171422639","title":"Hoth Therapeutics公布积极数据：EGFR抑制剂治疗中无患者需减量或停药","url":"https://stock-news.laohu8.com/highlight/detail?id=1171422639","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171422639?lang=zh_cn&edition=full","pubTime":"2026-05-06 04:18","pubTimestamp":1778012297,"startTime":"0","endTime":"0","summary":"生物制药公司Hoth Therapeutics Inc宣布了一项关于其EGFR抑制剂疗法的积极进展。在相关临床观察中，接受该治疗方案的患者群体表现出良好的耐受性，目前没有患者因不良反应而需要降低药物剂量或中止治疗。\n这一结果具有重要意义，因为它初步表明该疗法可能在维持预期疗效的同时，有效控制了潜在的副作用。对于依赖EGFR抑制剂路径的癌症治疗而言，维持足额剂量治疗的连续性通常是影响疗效的关键因素之一。此次数据的公布为Hoth Therapeutics的后续临床开发提供了支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131399950","title":"Hoth Therapeutics公司HT-001试验取得积极成果：超65%患者报告疼痛与瘙痒显著缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1131399950","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131399950?lang=zh_cn&edition=full","pubTime":"2026-05-06 04:18","pubTimestamp":1778012297,"startTime":"0","endTime":"0","summary":"在Hoth Therapeutics公司最新公布的HT-001临床试验数据中，超过65%的受试者反馈其疼痛与瘙痒症状获得显著改善。该试验结果展现了候选药物在缓解患者临床症状方面的潜力，为后续研发进程提供了重要数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128744078","title":"Hoth Therapeutics获西班牙授权开展HT-001二期a阶段试验 中期数据彰显对癌症患者显著疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1128744078","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128744078?lang=zh_cn&edition=full","pubTime":"2026-05-06 04:17","pubTimestamp":1778012240,"startTime":"0","endTime":"0","summary":"生物制药公司Hoth Therapeutics宣布，其创新疗法HT-001已获得西班牙监管机构批准开展二期a阶段临床试验。此次欧洲授权标志着该药物研发进程中的重要里程碑。\n最新披露的中期数据显示，HT-001在癌症患者群体中表现出令人鼓舞的治疗效果。试验结果初步证实了该疗法在控制肿瘤进展和改善患者临床症状方面的潜力。\n获得西班牙药监部门的认可，为Hoth Therapeutics在欧洲市场进一步推进临床研究奠定了坚实基础。公司计划基于现有数据优化后续试验方案，加速HT-001的全球化开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149943911","title":"Hoth Therapeutics 计划将 HT-VA 研究成果推进至更多临床前验证研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1149943911","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149943911?lang=zh_cn&edition=full","pubTime":"2026-04-14 19:05","pubTimestamp":1776164704,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics 宣布将把其 HT-VA 项目的关键发现推进至额外的临床前验证研究阶段。这一举措旨在进一步评估该候选疗法的有效性与安全性，为后续开发奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188422004","title":"Hoth Therapeutics：GDNF在MAFLD与肥胖模型中显著降低SREBF1并提升PPARα","url":"https://stock-news.laohu8.com/highlight/detail?id=1188422004","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188422004?lang=zh_cn&edition=full","pubTime":"2026-04-14 05:25","pubTimestamp":1776115540,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics公司公布的研究数据显示，其关注的胶质细胞源性神经营养因子（GDNF）在代谢相关脂肪性肝病（MAFLD）与肥胖实验模型中表现出显著作用。该因子能够有效降低固醇调节元件结合转录因子1（SREBF1）的表达水平，同时促进过氧化物酶体增殖物激活受体α（PPARα）的活性提升。\n这一发现为开发针对代谢紊乱相关疾病的创新疗法提供了新的分子机制依据，突显了GDNF在调节脂质代谢通路中的潜在治疗价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171005149","title":"Hoth Therapeutics公布HT-VA CRADA积极数据：GDNF重构肝脏脂肪代谢机制，关闭脂肪生成基因并激活燃脂通路，效果优于司美格鲁肽","url":"https://stock-news.laohu8.com/highlight/detail?id=1171005149","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171005149?lang=zh_cn&edition=full","pubTime":"2026-04-14 05:25","pubTimestamp":1776115524,"startTime":"0","endTime":"0","summary":"生物制药公司Hoth Therapeutics最新发布的HT-VA合作研发协议数据取得突破性进展。研究显示，胶质细胞源性神经营养因子能够重塑肝脏脂肪代谢系统，成功抑制脂肪合成基因的表达，同时激活多条脂肪分解代谢通路。值得注意的是，该疗法在临床前研究中表现出优于糖尿病药物司美格鲁肽的代谢调节能力。\n实验数据揭示，GDNF通过调控肝脏细胞能量代谢的关键节点，实现脂肪代谢的双向调节：一方面有效阻断新生脂肪的积累途径，另一方面显著提升脂肪酸氧化效率。这种独特的作用机制为治疗代谢性疾病提供了新的方向，尤其对非酒精性脂肪肝等疾病具有潜在治疗价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HOTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131915652","title":"Hoth Therapeutics预计西班牙与波兰监管审批在即 试验站点即将启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1131915652","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131915652?lang=zh_cn&edition=full","pubTime":"2026-04-01 20:17","pubTimestamp":1775045833,"startTime":"0","endTime":"0","summary":"生物制药公司Hoth Therapeutics近日透露，其针对特应性皮炎的新型疗法已向西班牙与波兰监管机构提交审批申请，预计短期内将获得通过。这意味着该公司位于两国的临床试验站点有望迅速投入运营，加速推进其创新药物的国际化布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HOTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118216933","title":"匈牙利批准扩大临床试验，因HT-001中期分析达主要终点，患者第六周实现ARIGA≤1","url":"https://stock-news.laohu8.com/highlight/detail?id=1118216933","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118216933?lang=zh_cn&edition=full","pubTime":"2026-04-01 20:17","pubTimestamp":1775045830,"startTime":"0","endTime":"0","summary":"匈牙利监管机构已批准扩大HT-001的临床试验规模。这一决定基于该药物在中期分析中成功达到主要研究终点——数据显示，参与试验的患者在第六周时ARIGA评分已降至≤1水平。\nHT-001由生物制药公司Hoth Therapeutics研发，此次中期分析结果为其疗效提供了有力支持。ARIGA指标是评估治疗反应的关键参数，数值≤1代表临床症状获得显著改善。试验数据的积极进展，为后续研究奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HOTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188249439","title":"Hoth Therapeutics公布HT-001积极数据：EGFR疗法相关皮肤毒性患者药物暴露量提升约77%且全身吸收极低","url":"https://stock-news.laohu8.com/highlight/detail?id=1188249439","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188249439?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:14","pubTimestamp":1774354455,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics最新公布的临床研究数据显示，其针对EGFR抑制剂引发皮肤毒性的抗癌患者研发的HT-001疗法，在药代动力学、安全性及临床活性方面表现积极。数据显示，该疗法可使局部药物暴露量提升约77%，同时全身系统性吸收维持在极低水平。\n该结果印证了HT-001通过局部给药精准靶向皮肤毒性的治疗策略，在维持有效局部药物浓度的同时，最大限度降低了全身性副作用风险。这一特性对于需要长期接受EGFR靶向治疗的癌症患者具有重要临床意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140710087","title":"Hoth Therapeutics公布积极雌性临床前数据，显示HT-VA在MASLD模型中恢复胆固醇水平并改善脂质代谢","url":"https://stock-news.laohu8.com/highlight/detail?id=1140710087","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140710087?lang=zh_cn&edition=full","pubTime":"2026-03-10 20:14","pubTimestamp":1773144894,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics发布的最新雌性临床前研究数据显示，其候选药物HT-VA在代谢相关脂肪肝病（MASLD）动物模型中表现出显著疗效。实验结果表明，HT-VA能够有效恢复机体的胆固醇平衡，并优化脂质代谢通路。这一突破为开发针对代谢性肝病的新型疗法提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HOTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189620458","title":"Hoth Therapeutics公司公布Cleer-001中期数据：队列患者100%达到主要疗效终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1189620458","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189620458?lang=zh_cn&edition=full","pubTime":"2026-02-25 05:17","pubTimestamp":1771967841,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics公司最新发布的Cleer-001中期临床试验数据显示，该研究队列中的所有患者均成功达到了预设的主要疗效终点，这一结果标志着候选疗法在目标患者群体中展现出显著的临床潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158626179","title":"Hoth Therapeutics 因患者需求增加，增设新临床中心加速 HT-001 试验入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1158626179","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158626179?lang=zh_cn&edition=full","pubTime":"2026-02-25 05:15","pubTimestamp":1771967741,"startTime":"0","endTime":"0","summary":"随着患者需求显著上升，Hoth Therapeutics 正通过增设新的临床研究中心，全力加快其核心候选药物 HT-001 的临床试验患者入组进程。\n这一战略举措旨在高效应对日益增长的患者参与意愿，确保试验能够按计划甚至提前推进，从而为后续的药物开发奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120538790","title":"Hoth Therapeutics：GDNF疗法使体重增长减缓10-15%，治疗末期趋于稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1120538790","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120538790?lang=zh_cn&edition=full","pubTime":"2026-02-10 21:33","pubTimestamp":1770730393,"startTime":"0","endTime":"0","summary":"生物制药公司Hoth Therapeutics宣布，其研发的GDNF疗法在实验研究中展现出显著效果——能够将体重增长幅度抑制10%至15%。值得注意的是，在治疗周期的最后几周，受试者的体重数据进入平台期，不再呈现明显上升趋势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HOTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175429669","title":"Hoth Therapeutics：匈牙利、西班牙及波兰的国别第二部分监管决定预计于2026年1月19日前公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1175429669","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175429669?lang=zh_cn&edition=full","pubTime":"2026-01-15 21:19","pubTimestamp":1768483154,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics公司宣布，针对其产品在匈牙利、西班牙和波兰的国别第二部分监管审批决定，预计将在2026年1月19日前作出。这一关键进展将直接影响该公司在欧洲市场的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185056438","title":"Hoth Therapeutics 迎来欧盟关键监管节点，推动HT-001肿瘤试验在多国启动临床中心","url":"https://stock-news.laohu8.com/highlight/detail?id=1185056438","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185056438?lang=zh_cn&edition=full","pubTime":"2026-01-15 21:19","pubTimestamp":1768483153,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics近日迎来其在欧盟监管流程中的关键转折点，为公司核心肿瘤疗法HT-001的临床试验铺平道路。这一进展将直接推动试验方案在多个欧洲国家启动临床研究中心，加速全球研发布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HOTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163130191","title":"Hoth Therapeutics发布全面管线更新，强调临床进展、孤儿药Ht-Kit的推进、Ht-001第二阶段的推进及新Gdnf代谢项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1163130191","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163130191?lang=zh_cn&edition=full","pubTime":"2025-12-04 03:00","pubTimestamp":1764788436,"startTime":"0","endTime":"0","summary":"Hoth Therapeutics发布全面管线更新，强调临床进展、孤儿药Ht-Kit的推进、Ht-001第二阶段的推进及新Gdnf代谢项目","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518222824","title":"Hoth Therapeutics, Inc.盘中异动 股价大跌5.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518222824","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518222824?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:33","pubTimestamp":1741613630,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时33分，Hoth Therapeutics, Inc.股票出现异动，股价大幅下跌5.50%。截至发稿，该股报1.03美元/股，成交量24.2463万股，换手率1.84%，振幅3.67%。Hoth Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.08%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Biodexa Pharmaceuticals Plc涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2087.41%、410.08%、63.40%，振幅较大的相关个股有Akero Therapeutics, Inc.、Xencor, Inc.、Seer, Inc.，振幅分别为100.05%、99.13%、98.72%。Hoth Therapeutics, Inc.公司简介：Hoth Therapeutics Inc是一家处于发展阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213350a26a257f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213350a26a257f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","HOTH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517948865","title":"Hoth Therapeutics, Inc.盘中异动 早盘股价大跌5.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517948865","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517948865?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:32","pubTimestamp":1741185179,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时32分，Hoth Therapeutics, Inc.股票出现波动，股价快速跳水5.65%。截至发稿，该股报1.17美元/股，成交量62.9736万股，换手率4.79%，振幅8.06%。Hoth Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Zyversa Therapeutics, Inc.较为活跃，换手率分别为355.98%、258.41%、187.27%，振幅较大的相关个股有Aditxt, Inc.、Silexion Therapeutics Corp、Invivyd, Inc.，振幅分别为23.90%、15.31%、13.32%。Hoth Therapeutics, Inc.公司简介：Hoth Therapeutics Inc是一家处于发展阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223300963adc99&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223300963adc99&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","HOTH","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hoththerapeutics.com","stockEarnings":[{"period":"1week","weight":0.971},{"period":"1month","weight":0.9034},{"period":"3month","weight":0.3465},{"period":"6month","weight":0.124},{"period":"1year","weight":0.5681},{"period":"ytd","weight":0.3737}],"compareEarnings":[{"period":"1week","weight":0.0145},{"period":"1month","weight":0.0631},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.107},{"period":"1year","weight":0.2821},{"period":"ytd","weight":0.1093}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Hoth Therapeutics, Inc.于2017年5月16日根据内华达州法律注册成立。该公司是一家临床阶段的生物制药公司，专注于为未满足的医疗需求开发新一代疗法。其研发管线包括针对肿瘤治疗相关副作用、肥大细胞源性癌症、神经炎症性疾病及其他适应症的候选药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.142857,"avgChangeRate":-0.045454},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.09197},{"month":3,"riseRate":0.375,"avgChangeRate":-0.064963},{"month":4,"riseRate":0.25,"avgChangeRate":-0.105303},{"month":5,"riseRate":0.25,"avgChangeRate":0.055272},{"month":6,"riseRate":0.428571,"avgChangeRate":0.131646},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.05884},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.030926},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.061813},{"month":10,"riseRate":0,"avgChangeRate":-0.17286},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.033966},{"month":12,"riseRate":0.571429,"avgChangeRate":0.193643}],"exchange":"NASDAQ","name":"Hoth Therapeutics","nameEN":"Hoth Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Hoth Therapeutics(HOTH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Hoth Therapeutics(HOTH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Hoth Therapeutics,HOTH,Hoth Therapeutics股票,Hoth Therapeutics股票老虎,Hoth Therapeutics股票老虎国际,Hoth Therapeutics行情,Hoth Therapeutics股票行情,Hoth Therapeutics股价,Hoth Therapeutics股市,Hoth Therapeutics股票价格,Hoth Therapeutics股票交易,Hoth Therapeutics股票购买,Hoth Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Hoth Therapeutics(HOTH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Hoth Therapeutics(HOTH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}